MannKind Corporation (MNKD) has been under a strong bear grip, hence the stock is down -27.02% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.38% in the past 1 week. The stock has risen by 0.91% in the past week indicating that the buyers are active at lower levels, but the stock is down -28.5% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 11.19% and the 50-Day Moving Average is 24.27%.The 200 Day SMA reached 40.44% MannKind Corp. has dropped 30.89% during the last 3-month period . Year-to-Date the stock performance stands at -51.86%.
The shares have received a consensus rating of Sell for the current week MannKind Corporation (NASDAQ:MNKD): stock was range-bound between the intraday low of $0.673 and the intraday high of $0.71 after having opened at $0.71 on Fridays session. The stock finally closed in the red at $0.71, a loss of -1.02%. The stock remained in the red for the whole trading day. The total traded volume was 4,273,513 shares. The stock failed to cross $0.71 in Fridays trading. The stocks closing price on Thursday was $0.698.
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Companys product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Companys Technosphere powders are -based on the Companys fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.